https://www.selleckchem.com/products/i-138.html
A significant improvement in Patient's evaluation of Global Assessment of Symptoms (p 0.05) and Patient Assessment of Constipation - Quality Of Life (PAC-QOL) (p 0.01) was observed in Group A compared to Group B. Drotaverine was significantly superior in efficacy as compared to Mebeverine in alleviating pain severity (starting from day 3), frequency and stools-elated symptoms of IBS. Drotaverine was significantly superior in efficacy as compared to Mebeverine in alleviating pain severity (starting from day 3), frequency and stoo
Like
Comment
Share
